Actos Caused Bladder Cancer and Wrongful Death of Wisconsin Man, Alleges Lawsuit Filed by Parker Waichman LLP

Share Article

Parker Waichman LLP has filed a lawsuit alleging that Actos (pioglitazone) caused bladder cancer and the subsequent wrongful death of a Wisconsin man. The suit was filed on behalf of the Decedent’s wife, who alleges that his injuries were a direct result of using Actos.

News Image

Parker Waichman LLP, a national law firm dedicated to protecting victims of defective drugs, has filed a lawsuit on behalf of a woman who alleges that Actos caused bladder cancer and the subsequent death of her husband. The suit was filed on November 16th in the U.S. District Court for the Western District of Louisiana, Lafayette Division (Case No. 6:12-cv-02886-RFD-PJH). The case has been filed into the Actos multidistrict litigation as part of the In Re: Actos (Pioglitazone) Products Liability Litigation (MDL No. 6:11-md-2299). Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals USA, Inc. f/k/a Takeda Pharmaceuticals North America, Inc., Takeda Pharmaceutical Company Limited and Eli Lilly and Company.

Actos is a Type 2 diabetes medication approved in 1999. It is part of the thiazolidinedione (TZD) drug class, which also includes the drug Avandia.

According to the Complaint, the Plaintiff’s Decedent started taking Actos in 2004 and developed bladder cancer in 2009. The Plaintiff’s Decedent died in October 2010, allegedly due to using Actos. The suit alleges that use of the drug caused extensive pain and suffering, severe emotional distress, and substantially reduced the Decedent’s ability to enjoy life. The lawsuit also alleges loss of consortium on behalf of the Decedent’s wife. The lawsuit also alleges that the Defendants failed to warn that Actos could cause bladder cancer. The suit claims that the Plaintiff’s Decedent would not have taken Actos if he were aware of the risks.

Last summer, the U.S. Food and Drug Administration (FDA) updated the safety label on Actos to warn that the medication could significantly increase the risk of bladder cancer after one year of use.

A number of research studies have linked Actos to an increased risk of bladder cancer. In August, the Journal of the National Cancer Institute published a study showing that Actos and other TZD drugs could increase the risk of bladder cancer when used long-term. The month prior, the Canadian Medical Association Journal found that patients who take Actos are 22 percent more likely to develop bladder cancer. Yet another study, published by the British Medical Journal in May 2012, found that the risk of bladder cancer doubled after two years. (

Parker Waichman LLP continues to offer free legal consultations to victims of Actos injuries, including bladder cancer, heart problems, and eye injuries. If you or a loved one were diagnosed with bladder cancer after taking Actos, please contact their office by visiting Free case evaluations are also available by calling 1 800 LAW INFO (1-800-529-4636).

Parker Waichman LLP
Gary Falkowitz, Managing Attorney
(800) LAW-INFO
(800) 529-4636

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Gary Falkowitz
Parker Waichman LLP
Email >
Follow us on
Visit website